160 results about "Fucose" patented technology

The use of a nutritional composition in the preparation of a food product for assisting in improving the memory ability in offspring, wherein the nutritional composition contains the following essential components: an active folic acid substance and fucosyllactose; and in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015):(0.5-10). The food product exerts the effect of assisting in improving the memory ability in offspring, wherein the food product is ingested by a mother, the mother is preganant and / or lactating, and the offspring comprises fetal offspring and / or infant offspring and optionally childhood offspring.

The invention provides a series of GDP-mannose dehydratase polypeptides which can be applied to synthesis of GDP-fucose, and belongs to the technical field of enzyme engineering. The GDP-mannose dehydratase polypeptide comprises a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide shown in SEQ ID NO: 1, or a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide M1-13. The GDP-mannose dehydratase polypeptide disclosed by the invention has relatively high catalytic activity.

The present application relates to a series of GDP-fucose synthetase polypeptides, which can be applied to the synthesis of human milk oligosaccharides (HMOs) precursor GDP-fucose, belonging to the field of enzyme engineering technology. In certain embodiments, the polypeptide having catalytic GDP-4-keto-6-deoxymannose converted into GDP-fucose comprises an amino acid sequence which is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identical to SEQ ID NO: 1 and / or to the polypeptide M1-14. The present application provides a series of polypeptides for synthesizing GDP-fucose.

The application discloses a kind of based on fermentation of Sanghuangjun preparation's Radix Tetrastigae polysaccharide and its use.The Radix Tetrastigae polysaccharide is composed of polysaccharide with weight percentage content more than 99%;The polysaccharide is composed of galactose, mannose, fucose and 3-O-methyl-galactose, and the molar ratio is 8.5-11.0:1.5-3:0.8-1.5:1.0.The Radix Tetrastigae polysaccharide is extracted, separated and purified from Sanghuang fermentation Radix Tetrastigae.The Radix Tetrastigae polysaccharide has significant antitumor activity and regulates intestinal flora structure efficacy, can be directly used as antitumor and / or regulate intestinal flora structure function product, and also can be used for preparing antitumor and / or regulating intestinal flora structure function product.

The present invention relates to nutritional compositions comprising digestible carbohydrates, lipids, proteins, 3-fucosyl lactose (3-FL) and a butyrate source, which are suitable for providing nutrition to an infant or young child suffering from or at risk of developing a food allergy, preferably cow milk protein or egg allergy, wherein the protein is or consists essentially of hydrolysed protein and / or free amino acids, and wherein the butyrate is provided in the form of dietary butyrate and / or by non-digestible saccharides selected from non-digestible polysaccharides, non-digestible oligosaccharides or mixtures thereof capable of undergoing microbial fermentation in the gastrointestinal tract to produce butyrate, and uses thereof.

The invention discloses a composition for preventing and / or treating alcoholic liver diseases, a product and application thereof. The present invention relates to a composition comprising: breast milk oligosaccharides and vitamins; the breast milk oligosaccharide comprises fucosyllactose and sialic acid lactose; the composition can provide nutritional support for patients with alcoholic liver diseases, repair intestinal mucosal barrier, reduce endotoxin entering blood, improve abundance of beneficial bacteria in intestinal tracts and reduce inflammatory response, so as to achieve the purpose of preventing and / or treating alcoholic liver diseases induced by alcohol.

The present invention relates to a monoclonal antibody reacting with a glycopeptide and use thereof. The present invention provides a monoclonal antibody which is an epitope of both a fucose moiety and an amino acid of a peptide moiety. The antibody of the present invention is a monoclonal antibody reacting with a glycopeptide containing a core fucose and an amino acid of 4 or more residues continuously from an asparagine of an additional sugar chain toward a C-terminal side, the antibody being an epitope of both the core fucose of the glycopeptide and an amino acid of the glycopeptide which is 3 or more residues from the asparagine of the additional sugar chain toward the C-terminal side.

The invention provides yellow-rose yellow-meat boletus fucomannan as well as a composition, a preparation method and application thereof, and belongs to the technical field of biological medicine mass health. The fucomannan has a structure represented by a general formula in an attached drawing of the abstract, and n represents the number of sugar repeating units and is a natural number. The weight-average molecular weight of the fucose glucomannan galactan of the boletus fucose is 10 kDa to 20 kDa, the polydispersity coefficient of the fucose glucomannan galactan is 1 to 2, and the molar ratio of glucose to mannose to fucose to galactose is 1.00 to 3.08 to 2.84 to 14.86. The boletus fucomannan and the composition containing the boletus fucomannan and the composition containing the boletus fucomannan and the composition containing the boletus fucomannan have the effects of promoting proliferation of beneficial bacteria, reducing the pH value of a microenvironment, increasing secretion of SCFAs and lactic acid, adjusting composition of intestinal microorganisms and the like, and have the function of improving the intestinal microecology. Therefore, the invention also discloses the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan-glucomannan of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the boletus roseus and the fucomannan of the composition of the composition of the composition of the composition of the composition of the composition of the composition of

This invention relates to the field of lyophilized formulation technology, specifically disclosing an esupagglutide α-nano-lyophilized micelle and its preparation method. The micelles of this invention utilize polylactic-co-hydroxyacetic acid copolymer and sodium phosphatidylglycerol as micelle carriers, with arginine and cysteine ​​providing branching synergistic effects. Homogenization via film formation and low-temperature lyophilization yield lyophilized nano-micelle powder. The nano-micelle powder reduces protein oxidative decomposition during lyophilization, decreases impurity fragments, and reduces various non-fucose glycosylation, basic components (succinimide, methionine oxidation products), N-terminal deletion, Asn deamidation, and Met and Trp residue oxidation impurities that affect product quality. Product quality analysis and animal experiments after reconstitution show good resistance to impurities and degradation risk. The reconstituted esupagglutide α-nano-micelle system exhibits better stability and sustained-release properties, enhancing the hypoglycemic sustained-release effect 72 hours after injection, significantly improving upon conventional non-micelle formulations.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The invention relates to the technical field of cosmetics, in particular to a skin care product composition containing deep sea water mineral powder as well as a preparation method and application of the skin care product composition. The skin care product composition is prepared from deep sea water mineral powder, butanediol, glycerin, trehalose, DNA sodium, fucose, adenosine, nicotinamide, hydrolyzed hyaluronic acid, sodium hyaluronate, allantoin, dipotassium glycyrrhizinate, a licorice root extract, a white perilla leaf extract, an angelica koreana root extract, a herba houttuyniae extract, a pinus densiflora leaf extract, sodium polyacrylate, EDTA disodium and phenoxyethanol. The preservative is prepared from the following raw materials: chlorphenesin, 1, 2-hexanediol, lactobacillus fermentation lysate and deionized water. The skin care product composition can synergistically promote collagen synthesis, improve skin roughness, improve glossiness and repair a barrier, and has the characteristics of stability and safety.

The application provides a key enzyme involved in glycosylation modification of triterpene saponins, and an application thereof, and belongs to the technical field of genetic engineering. The glycosyltransferase gene is screened based on the omics research of the base plant of traditional Chinese medicine Duanxueliu, i.e. clinopodium gracile, and a pET28a-MBP-CcGT-g51295 prokaryotic expression vector is constructed to successfully obtain the glycosyltransferase. It is found that the glycosyltransferase can catalyze Saikogenin A and Saikogenin F to generate Prosaikogenin A and Prosaikogenin F respectively by using a glycosyl donor UDP-fucose; can catalyze Saikogenin A to generate clinopodiside I and clinopodiside X by using UDP-glucose; can catalyze Prosaikogenin A to generate Saikosaponin B1, Saikosaponin c1 and Saikosaponin X by using UDP-glucose; and can catalyze Prosaikogenin F to generate Saikosaponin A and Buddlejasaponin IV by using UDP-glucose, which reveals the catalytic function of the glycosyltransferase and provides a gene component for the biological research of triterpene saponins, and solves the problem of biological resources of rare saponins.

The invention discloses marsdenia tenacissima herb residue polysaccharide as well as a preparation method and application thereof. The invention discloses marsdenia tenacissima herb residue polysaccharide, the marsdenia tenacissima herb residue polysaccharide comprises TGT-1 or TGT-2, the average molecular weight of the TGT-1 is 19.929 kDa, the TGT-1 is composed of mannose, rhamnose, fucose, glucose and galactose, and the molar ratio of the mannose to the rhamnose to the fucose to the glucose to the galactose is 1: 1.11: 0.57: 22.62: 3.96; the average molecular weight of the TGT-2 is 11.762 kDa, the TGT-2 is composed of mannose, fucose, glucose and galactose, and the molar ratio of the mannose to the fucose to the glucose to the galactose is 2.01: 1: 35.21: 1.55. The polysaccharide components TGT-1 and TGT-2 are separated out, and the marsdenia tenacissima herb residue polysaccharide nano-selenium compound is prepared and has oxidation resistance and antitumor activity.

The present application provides a nutritional composition for improving intestinal inflammation and microbial imbalance and application thereof. Specifically, the present application provides application of a composition in preparation of a product for improving intestinal inflammation and / or microbial imbalance, wherein the composition comprises 2'-fucosyllactose and lacto-N-neotetraose, and the mass ratio of 2'-fucosyllactose to lacto-N-neotetraose is (1-5.5):1. The present application also provides a food containing the composition, and application of the composition or the food in preparation of a product for improving intestinal inflammation and microbial imbalance.

The present application belongs to the technical field of application of fungal polysaccharides, and particularly relates to a Boletus edulis fruiting body polysaccharide as well as a preparation method and application thereof. Polysaccharides in Boletus edulis fruiting bodies are extracted, and the chemical structure of BDP-F is characterized by ultraviolet-visible light, Fourier transform infrared spectroscopy, one-dimensional nuclear magnetic resonance and two-dimensional nuclear magnetic resonance. The research results show that BDP-F is mainly composed of mannose, glucose, galactose and fucose. Methylation and nuclear magnetic resonance analysis show that the glycosidic bond of BDP-F is (1→6)-alpha-d-galactose, the main chain is composed of ->6)-alpha-d-galp-(1→ residues, and the O-2 position is branched by alpha-L-Fucp-(1→ and alpha-D-Manp-(1→ residues. Through DPPH free radical, hydroxyl radical and superoxide anion radical scavenging experiments, it is shown that BDP-F has the ability to serve as a natural antioxidant, and BDP-F can also reduce alcohol-induced GES-1 cell damage through antioxidant and anti-inflammatory effects within the experimental concentration range.

The invention relates to a yeast gene modified cell containing GDP-fucose synthase polypeptide, which can be applied to synthesis of human milk oligosaccharide, and belongs to the technical field of gene engineering. According to the technical scheme, the yeast gene modified cell contains a heterologous nucleic acid sequence of a GDP-fucose synthase active polypeptide. The synthetase active polypeptide is obtained by modifying at least one site of the 20th site to the 29th site, the 40th site to the 53th site, the 75th site to the 81st site, the 95th site, the 148th site to the 158th site, the 193th site, the 215th site, the 219th site to the 21st site, the 227th site to the 232 site, the 239th site to the 241st site, the 259th site to the 264th site, the 301st site to the 302 site, the 306th site and the 310th site to the 316th site of an amino acid sequence shown in SEQ ID NO: 1. Compared with an original strain, the yeast gene modified cell has higher activity of synthesizing fucosyllactose, and a safe and feasible technical scheme is provided for industrial production of fucosyllactose.

The invention discloses bifidobacterium animalis subsp. Lactis CCMXJ2003 as well as a composition and application thereof, and belongs to the technical field of microbial preparations. In order to screen a specific probiotic strain which can form efficient synergy with 2 '-fucosyllactose and has good viability and an immunoregulation function, and construct a precise micro-ecological intervention scheme aiming at atopic dermatitis immunopathology key links, the invention provides a microecological intervention method for the atopic dermatitis immunopathology key links. The invention provides the bifidobacterium animalis subsp. Lactis CCMXJ2003 capable of efficiently utilizing the 2 '-fucosyllactose, and an in-vivo experiment proves that the composition of the 2'-fucosyllactose and the bifidobacterium animalis subsp. Lactis CCMXJ2003 shows an obvious enhancement effect in the aspect of relieving the specific dermatitis; the compound has a wide application prospect in prevention and / or treatment of atopic dermatitis.

The application discloses a streptococcus and application thereof, and belongs to the technical field of microorganisms. The application screens a streptococcus capable of decomposing and utilizing breast milk oligosaccharides, and the streptococcus can grow by taking breast milk oligosaccharides as a carbon source, the utilization rate of 2'-fucosyllactose, 6'-sialyllactose and lacto-N-tetraose reaches more than 99.80%, and the streptococcus is helpful to promoting the growth of short bifidobacterium which cannot utilize 6'-SL.

The invention relates to lentinan as well as a preparation method and application thereof, monosaccharide of the lentinan comprises glucose, galactose, mannose, fucose and glucosamine, and the molar ratio of the glucose to the galactose to the mannose to the fucose to the glucosamine is (85.0 to 88.0) to (5.5 to 6.5) to (3.5 to 4.1) to (1.8 to 2.2) to (1.0 to 1.2). According to the preparation method disclosed by the invention, a composite filler consisting of AB-8 macroporous resin and acidic aluminum oxide is adopted, static adsorption decoloration is carried out when the optimal mass ratio is 2: 3, an extraction process of combining graded hot water extraction with negative pressure concentration is optimized, and on the premise of avoiding using an organic solvent, efficient purification of lentinan is realized, so that the retention rate of the lentinan reaches 22.38%, and the yield of the lentinan is improved. And the beta-triple helix active structure can be well reserved.

The present application belongs to the technical field of sugarcane leaf polysaccharide regulating intestinal flora. The present application provides a sugarcane leaf polysaccharide composition, which comprises mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose, xylose, arabinose and fucose in a mass ratio of 6.8:1.5:5.2:40.7:13.1:18.9:1.6:6.1:1.9. The composition of the present application can improve the imbalance of intestinal flora caused by obesity and hyperglycemia by reducing the ratio of Firmicutes / Bacteroidetes and increasing the abundance of probiotics.

The invention provides a fermentation method for efficiently producing fucose by using genetically engineered bacteria, the preservation number of the genetically engineered bacteria is CCTCC NO: M 20252837, and the fermentation method comprises the following steps: S1, preparing a seed culture medium, a fermentation culture medium and a fed-batch culture medium; wherein the fed-batch culture medium contains glucose and glycerol in a mass ratio of (1-2): 1; s2, inoculating the genetically engineered bacteria into a seed culture medium, and culturing to obtain a seed solution; s3, inoculating the seed solution into a fermentation culture medium, and controlling the temperature to be 35-37 DEG C, the pH to be 7.0 and the dissolved oxygen to be greater than or equal to 30%; when dissolved oxygen is increased to 60% or above, culture conditions are controlled in four stages for culture; and when the OD600 value is reduced, putting into a tank for centrifugation, and collecting supernate to finish fermentation. The fucose is produced by a fermentation process designed for specific engineering bacteria, the product yield is high, the purity is high, and the method is suitable for industrial production and application.

The application discloses a chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity and application thereof, and belongs to the field of biological medicines. The application adopts a method for extracting chaga polysaccharide by boiling water and precipitating chaga polysaccharide by ethanol, and combines DEAE cellulose column purification technology, and successfully realizes separation of chaga polysaccharide by using the principle that macromolecular polysaccharide is insoluble in organic solvents, and obtains chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity. The monosaccharide composition of the chaga acidic polysaccharide IOP-2 includes fucose 0.71%, rhamnose 3.33%, arabinose 2.18%, galactose 2.92%, glucose 80.59%, xylan 3.46% and mannose 6.81% in terms of molar percentage. The significant effect of the chaga acidic polysaccharide IOP-2 on anti-thyroid cancer is verified through in-vivo and in-vitro experiments, and a new treatment method is provided for clinical treatment of thyroid cancer.

The invention provides a purification method for efficiently producing fucose by using genetically engineered bacteria, the preservation number of the genetically engineered bacteria is CCTCC NO: M 20252837, fermentation liquor of the genetically engineered bacteria is purified, and the purification method comprises the following specific steps: S1, taking the fermentation liquor, and filtering by using a ceramic membrane to obtain filtrate I; s2, adding a decolorizing agent into the filtrate I, stirring and decolorizing, and filtering through a filtering membrane to obtain filtrate II; s3, performing ultrafiltration on the filtrate II, performing top washing with pure water, and collecting all filtrate to obtain filtrate III; s4, sequentially carrying out cationic resin and anion resin combined chromatography on the filtrate III to obtain a chromatographic solution; s5, performing electrodialysis desalination on the chromatographic solution until the conductivity is 1t; the concentration is 100 [mu] s / cm; s6, concentrating the desalted solution, adding absolute ethyl alcohol, firstly heating and stirring, and then cooling until stirring, so as to obtain a turbid liquid; s7, the turbid liquid is filtered, solid is eluted with absolute ethyl alcohol, vacuum drying is conducted, and fucose is obtained. The purification method provided by the invention has the advantages of high purity, high yield and short period, and is suitable for industrial production.

The invention discloses a sea cucumber feed as well as a preparation method and application thereof, and belongs to the technical field of sea cucumber feed preparation. According to the technical scheme, every 100 g of feed comprises 40 g of sea mud, 15-25 g of gulfweed powder, 5-15 g of enzymolysis gulfweed liquid and 1 g of multi-vitamin multi-mineral premix. The dosage of the enzymolysis gulfweed liquid is calculated according to the dry weight of the gulfweed, and the enzymolysis gulfweed liquid is obtained by performing enzymolysis on the gulfweed through algin degrading enzyme, pectinase and cellulase. The sea cucumber feed is applied to the aspect of sea cucumber feeding, solves the problem that the existing sea cucumber feed still cannot well promote accumulation of sea cucumber saponin and fucose in the body wall of the sea cucumber so as not to improve the nutritional value of the sea cucumber, and can effectively promote accumulation of sea cucumber saponin and fucose in the body wall of the sea cucumber so as to improve the nutritional value of the sea cucumber.

The application relates to the technical field of engineering bacteria, and particularly discloses recombinant Escherichia coli for synthesizing fucosyllactose as well as a construction method and application thereof. In the genome of the recombinant Escherichia coli, phosphofructokinase genes or phosphofructokinase genes and pyruvate kinase genes are knocked out, so that glucose carbon flow is reduced to flow to a tricarboxylic acid cycle required for cell growth, and the intake of glucose carbon flow is forced to flow more to the synthesis of products (GDP-L-fucose in the synthesis of FL), and the synthesis efficiency of the products is improved. Meanwhile, the glucose carbon flow flowing to the cell growth is greatly reduced, and the glucose effect can be removed, so that the tolerance of the fermentation process to excessive glucose residues is improved, and the difficulty of downstream production amplification is reduced. The recombinant Escherichia coli uses glycerol and glucose compound carbon sources as raw materials, uses lactose as a substrate, and has a 3-fucosyllactose yield of 73.88 g / L in a 5L tank fermentation, which is the highest level reported at present.

The invention provides a prebiotic and probiotic compound for promoting bone health, which comprises 2 '-FL (2'-fucosyllactose) and plant lactobacillus Hi 188, and the 2 '-FL (2'-fucosyllactose) and the plant lactobacillus Hi 188 have a synergistic effect on promoting bone health.

The application provides a composition for promoting growth of Akkermansia and application, the composition comprises colostrum basic protein, beta-glucan and 2'-fucosyllactose, wherein, in the composition, the concentration ratio of the colostrum basic protein, beta-glucan and 2'-fucosyllactose is (0.025-0.3):(0.03-0.15):(0.6-2.5). The composition can fully meet the nutritional requirements of Akkermansia bacteria, especially mucinophilic Akkermansia bacteria, can effectively promote the growth of Akkermansia bacteria, can be used for culturing Akkermansia bacteria in vitro, and can promote the growth of mucinophilic Akkermansia bacteria in human intestinal tract, increase the potential probiotic Akkermansia bacteria in the intestinal tract, and improve intestinal health.

The invention belongs to the technical field of marine polysaccharides, and relates to an anti-hypoxia urechis unicinctus body cavity fluid sulfated polysaccharide as well as a preparation method and application thereof. The weight-average molecular weight of the polysaccharide is 1000-50000 Da, the mass fraction of sulfate radicals is 10.0%-30.0%, and monosaccharide is prepared from galactose, ribose, fucose, glucosamine, mannose and glucose. The preparation method comprises the following steps: inducing controlled degradation of a main chain through high-temperature hot water extraction, carrying out proteolysis deproteinization, carrying out graded ethanol precipitation interception and carrying out anion exchange chromatography purification. The polysaccharide shows a remarkable protective effect in a nerve cell hypoxia simulation model, has excellent free radical scavenging activity, and can be used for preparing medicines, antioxidants, functional foods and the like for preventing or treating hypoxia-related diseases.

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.